Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)

  • Technology appraisal
  • TA270
  • Published: 
Download guidance (PDF)

Overview

NICE is unable to make a recommendation about the use in the NHS of decitabine for acute myeloid leukaemia because no evidence submission was received from the manufacturer of the technology.

Last reviewed: 12 December 2012

Next review: We will review this decision if the company decides to make a submission.